Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Adam Cherry

Physician Assistant Longview, WA Physician Assistant

NPI 1770805673 CMS profile 10791667

1152 Douglas St, Longview, WA 98632

Open in the dashboard

General payments

$15,102

359 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Cherry of Longview, WA is reported in the CMS Open Payments database as having received $15,102 across 359 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,518 95
2024 General $5,458 51
2023 General $1,189 23
2022 General $3,000 93
2021 General $1,936 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Cherry
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Adam Cherry were reported at $3,518. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Adam Cherry Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,936 $132 $37–$438 $132
2022 $3,000 $155 $48–$522 $149
2023 $1,189 $167 $52–$557 $160
2024 $5,458 $178 $55–$600 $164
2025 $3,518 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. BioCryst US Sales Co., LLC $3,960 12 payments
  2. BioCryst Pharmaceuticals, Inc. $2,766 3 payments
  3. GlaxoSmithKline, LLC. $1,427 52 payments
  4. AstraZeneca Pharmaceuticals LP $1,425 59 payments
  5. CSL Behring $834 63 payments
  6. Regeneron Healthcare Solutions, Inc. $797 17 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $628 30 payments
  8. Amgen Inc. $382 17 payments
  9. Novartis Pharmaceuticals Corporation $349 15 payments
  10. kaleo, Inc. $266 10 payments
  11. Other $2,267 81 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,337 337 payments
  2. Consulting Fee $5,630 6 payments
  3. Travel and Lodging $1,338 2 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $750 1 payment
  5. Education $47 13 payments
Products named General payments · program years 2021–2025
  1. Orladeyo $2,548 11 payments
  2. DUPIXENT $721 14 payments
  3. Hizentra $561 40 payments
  4. AIRSUPRA $448 17 payments
  5. NUCALA $431 35 payments
  6. TEZSPIRE Respiratory $393 17 payments
  7. TEZSPIRE Inflammation $382 17 payments
  8. CUVITRU $374 18 payments
  9. FASENRA $291 13 payments
  10. Haegarda $273 23 payments
  11. Other $3,695 157 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

68

Median for Physician Assistant: 241

Drug cost

$3,627

Median for Physician Assistant: $4,110

Branded share of claims

39.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 14 $2,693
Albuterol Sulfate Hfa Albuterol Sulfate Brand 13 $445
Hydroxyzine Hcl Generic 16 $404
Prednisone Generic 12 $43
Montelukast Sodium Generic 13 $42

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$10,373

Medicare's payments for the services billed

Medicare patients

69

Average age 64

Services billed

1,093

51 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 49%
Arthritis 48%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $211
$211 — —
AYVAKIT
  • Blueprint Medicines Corporation $160
$160 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $50
  • Genentech USA, Inc. $48
$98 — —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $83
$83 — —
RUCONEST
  • Pharming Healthcare, Inc. $80
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

359 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record